P076 transferable immune reactive microbiota determine clinical and immunologic outcome of fecal microbiota transplantation for ulcerative colitis

Biologic therapy has significantly improved treatment for UC, but nearly two-thirds of patients attenuate response. Additional therapeutic modalities are therefore needed to address the underlying pathophysiology of UC. Fecal microbiota transplant (FMT) is an emerging therapy for the treatment of UC, but several randomized controlled trials have shown variable efficacy of FMT, and the microbial mechanisms responsible for clinical response are not well understood. Therefore, using samples from our pilot FMT study (Jacob, V, et  al Inflamm.

Source: Gastroenterology - January 25, 2020 Category: Gastroenterology Authors: Svetlana Lima, Lasha Gogokhia, Monica Viladomiu, Carl Crawford, Vinita Jacob, Ellen Scherl, Melissa Rosenthal, Su-Ellen Brown, John Hambor, Randy Longman Tags: Microbial-Based Therapy Source Type: research